Shelf-life analysis of scFOS produced by commercial FTase enzymes

[SPA] Los fructooligosacáridos decadena corta (scFOS) son oligosacáridos que tienen gran interés como prebióticos. La producción de scFOS mediante hidrólisis enzimática de la sacarosa es catalizada, entre otras, por la enzima fructosiltransferasa (FTasas). Estos productos seusancomo ingredientes de alimentos funcionalesasí como por sus propiedades tecnológicas. Al ser incluidos como parte de otros alimentos los scFOS pueden ser sometidos a diferentes pH y tratamientos térmicos durante el procesado o conservación. En este escenario, es interesante conocer la estabilidad de los scFOS producidos bajo diferentes condiciones de temperatura y pH. [ENG] The short-chain fructooligosaccharides (scFOS) are oligosaccharides that have a great interest as prebiotics. Fructosyltransferase enzymes (FTases) carry out the production of scFOS by enzymatic hydrolysis of sucrose. These products are used as functional food ingredients and also because of their technological properties. As a part of other foods, they can be included in matrices of different pH and be subjected to different heat treatments during processing or preservation. Therefore, it becomes necessary to study the stability of the scFOS produced under different conditions of temperature and pH.Este trabajo forma parte del Proyecto CDTI (ref. IDI-20141129), llevado a cabo en colaboración con la empresa Zukan S.L., que ha financiado estas investigaciones

Riego de tomate bajo invernadero con agua marina desalinizada y reutilización de drenajes

Poster presentado al XXXVII Congreso Nacional de Riegos, celebrado en Don Benito del 4 al 6 de Junio de 2019 y organizada por la Asociación Española de Riegos y Drenajes y la Universidad de ExtremaduraEvaluación agronómica y fisiológica del cultivo de tomate en hidropónico y en suelo enarenado, regado con AMD y mezclada con aguas salobres de diferente salinidad.Programa LIFE+ de la Unión Europea: Proyecto LIFE16-ENV-ES-00034

Riego de un cultivo de citricos con agua marina desalinizada. resultados preliminares en suelo y planta

La escasez de agua y la creciente presión sobre los recursos hídricos en las regiones semiáridas ha extendido la utilización para el riego de recursos hídricos no convencionales, como el agua marina desalinizada (AMD). Debido a su composición en Cl-, Na+ y B3+, el riego con AMD podría causar problemas agronómicos y afectar al suelo y a los cultivos a medio y largo plazo. En este estudio, se regó una parcela de mandarinos durante 20 meses con (i) agua proporcionada por la Comunidad de Regantes del Campo de Cartagena (CR), (ii) agua marina desalinizada (AMD) y (iii) mezcla de agua 50% CR y 50% AMD (AM). Se evaluó el efecto sobre la dinámica y acumulación de los iones tóxicos Cl-, Na+ y B3+ en el suelo y en la planta. La [B3+] del agua AMD fue superior a la de CR, acumulándose en el suelo, con una concentración un 25% superior a la encontrada con CR al final del ensayo. La [B3+] en la capa superficial del suelo se correlacionó con la [B3+] en el agua y con la [B3+] en la hoja. Aunque tras 20 meses los árboles regados con AMD tuvieron una [B3+] foliar un 25% superior a la de árboles regados con CR, no presentaron síntomas de toxicidad. Las [Cl-] y [Na+] del agua fueron similares en los tres tipos de agua, superando los umbrales a partir de los cuales pueden producir toxicidad en cítricos. Las concentraciones de Cl- y Na+ en hoja permanecieron por debajo del umbral de toxicidad establecido para cítricos. Los resultados obtenidos son preliminares ya que este estudio debería extenderse durante un periodo más largo para obtener datos más concluyentes acerca de los efectos a largo plazo de la utilización de AMD tanto en el suelo como en la planta

Impact of Moderate Heat, Carvacrol, and Thymol Treatments on the Viability, Injury, and Stress Response of Listeria monocytogenes

The microbial safety and stability of minimally processed foods are based on the application of combined preservative factors. Since microorganisms are able to develop adaptive networks to survive under conditions of stress, food safety may be affected, and therefore understanding of stress adaptive mechanisms plays a key role in designing safe food processing conditions. In the present study, the viability and the sublethal injury of Listeria monocytogenes exposed to moderate heat (55°C) and/or essential oil compounds (carvacrol and thymol, 0.3 mM) treatments were studied. Synergistic effects were obtained when combining mild heat (55°C) with one or both essential oil compounds, leading to inactivation kinetics values three to four times lower than when using heat alone. All the treatments applied caused some injury in the population. The injury levels ranged from around 20% of the surviving population under the mildest conditions to more than 99.99% under the most stringent conditions. Protein extracts of cells exposed to these treatments were analysed by two-dimensional gel electrophoresis. The results obtained revealed that stressed cells exhibited differential protein expression to control cells. The proteins upregulated under these stressing conditions were implicated, among other functions, in stress response, metabolism, and protein refolding

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Background: The benefit of pharmacogenetic testing before starting drug therapy has been well documented for several single gene–drug combinations. However, the clinical utility of a pre-emptive genotyping strategy using a pharmacogenetic panel has not been rigorously assessed. Methods: We conducted an open-label, multicentre, controlled, cluster-randomised, crossover implementation study of a 12-gene pharmacogenetic panel in 18 hospitals, nine community health centres, and 28 community pharmacies in seven European countries (Austria, Greece, Italy, the Netherlands, Slovenia, Spain, and the UK). Patients aged 18 years or older receiving a first prescription for a drug clinically recommended in the guidelines of the Dutch Pharmacogenetics Working Group (ie, the index drug) as part of routine care were eligible for inclusion. Exclusion criteria included previous genetic testing for a gene relevant to the index drug, a planned duration of treatment of less than 7 consecutive days, and severe renal or liver insufficiency. All patients gave written informed consent before taking part in the study. Participants were genotyped for 50 germline variants in 12 genes, and those with an actionable variant (ie, a drug–gene interaction test result for which the Dutch Pharmacogenetics Working Group [DPWG] recommended a change to standard-of-care drug treatment) were treated according to DPWG recommendations. Patients in the control group received standard treatment. To prepare clinicians for pre-emptive pharmacogenetic testing, local teams were educated during a site-initiation visit and online educational material was made available. The primary outcome was the occurrence of clinically relevant adverse drug reactions within the 12-week follow-up period. Analyses were irrespective of patient adherence to the DPWG guidelines. The primary analysis was done using a gatekeeping analysis, in which outcomes in people with an actionable drug–gene interaction in the study group versus the control group were compared, and only if the difference was statistically significant was an analysis done that included all of the patients in the study. Outcomes were compared between the study and control groups, both for patients with an actionable drug–gene interaction test result (ie, a result for which the DPWG recommended a change to standard-of-care drug treatment) and for all patients who received at least one dose of index drug. The safety analysis included all participants who received at least one dose of a study drug. This study is registered with ClinicalTrials.gov, NCT03093818 and is closed to new participants. Findings: Between March 7, 2017, and June 30, 2020, 41 696 patients were assessed for eligibility and 6944 (51·4 % female, 48·6% male; 97·7% self-reported European, Mediterranean, or Middle Eastern ethnicity) were enrolled and assigned to receive genotype-guided drug treatment (n=3342) or standard care (n=3602). 99 patients (52 [1·6%] of the study group and 47 [1·3%] of the control group) withdrew consent after group assignment. 652 participants (367 [11·0%] in the study group and 285 [7·9%] in the control group) were lost to follow-up. In patients with an actionable test result for the index drug (n=1558), a clinically relevant adverse drug reaction occurred in 152 (21·0%) of 725 patients in the study group and 231 (27·7%) of 833 patients in the control group (odds ratio [OR] 0·70 [95% CI 0·54–0·91]; p=0·0075), whereas for all patients, the incidence was 628 (21·5%) of 2923 patients in the study group and 934 (28·6%) of 3270 patients in the control group (OR 0·70 [95% CI 0·61–0·79]; p <0·0001). Interpretation: Genotype-guided treatment using a 12-gene pharmacogenetic panel significantly reduced the incidence of clinically relevant adverse drug reactions and was feasible across diverse European health-care system organisations and settings. Large-scale implementation could help to make drug therapy increasingly safe. Funding: European Union Horizon 2020